(RS)-3-Hydroxyphenylglycine

Discontinued Product

0324 has been discontinued.

View all Glutamate (Metabotropic) Group I Receptors products.
Description: Group I mGlu agonist
Alternative Names: (RS)-3H-PG
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for (RS)-3-Hydroxyphenylglycine

(RS)-3-Hydroxyphenylglycine is an agonist at PI-linked metabotropic glutamate receptors.

S-enantiomer also available.

Technical Data for (RS)-3-Hydroxyphenylglycine

M. Wt 167.16
Formula C8H9NO3
Storage Desiccate at RT
CAS Number 31932-87-3
PubChem ID 1217
InChI Key DQLYTFPAEVJTFM-UHFFFAOYSA-N
Smiles OC1=CC=CC(C(C(O)=O)N)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for (RS)-3-Hydroxyphenylglycine

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References for (RS)-3-Hydroxyphenylglycine

References are publications that support the biological activity of the product.

Birse et al (1993) Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system. Neuroscience 52 481 PMID: 7680790

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Agonists

Keywords: (RS)-3-Hydroxyphenylglycine, (RS)-3-Hydroxyphenylglycine supplier, Group, I, mGlur, agonists, Receptors, mGlu1, mGlu5, mGluR1, mGluR5, Glutamate, Metabotropic, (RS)-3H-PG, (Metabotropic), 0324, Tocris Bioscience

Citations for (RS)-3-Hydroxyphenylglycine

Citations are publications that use Tocris products.

Currently there are no citations for (RS)-3-Hydroxyphenylglycine.

Reviews for (RS)-3-Hydroxyphenylglycine

There are currently no reviews for this product. Be the first to review (RS)-3-Hydroxyphenylglycine and earn rewards!

Have you used (RS)-3-Hydroxyphenylglycine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.